Clinical trials: Multiple Sclerosis Brain Lesion
Relapse Remitting Multiple Sclerosis
A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
This was a randomized, partially blinded, placebo-controlled, non-confirmatory study to assess the effects of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relapsing-remitting…
- Trial name
- NCT02038049
- Testing
- VAY736
- Where
- 5 sites in United States, Czechia and 1 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-remitting Multiple Sclerosis
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
The purpose of this study was to determine the dose-response curve for the MRI-based efficacy of BAF312 compared with placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), and to characterize its safety and…
- Trial name
- NCT00879658
- Testing
- BAF312
- Where
- 72 sites in United States, Canada and 10 more
- Volunteers
- 297 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Heart Failure
LSFG-SKIN, Laser Speckle Flowgraphy
The purpose of this project is to quantify normal and abnormal skin blood flow regionally in different areas of the body(face, extremities, over burns and wounds) at baseline and over time in response to treatment or…
- Conditions
- Hypertension, Heart Failure, Vascular Ischemia, Burns
- Trial name
- NCT03660618
- Testing
- laser speckle flowgraphy
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Randy Kardon
Multiple Sclerosis, Relapsing-Remitting
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose…
- Trial name
- NCT00676715
- Testing
- Ocrelizumab, Avonex
- Where
- 84 sites in United States, Belgium and 16 more
- Volunteers
- 220 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis
Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis
This study will evaluate how improved cerebral blood flow affects the way in which newly formed MS lesions evolve and whether tissue repair is improved.
- Trial name
- perfuseMS (NCT02466074)
- Testing
- Acetazolamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The University of Texas Health Science Center, Houston
Multiple Sclerosis
Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
Background: Some multiple sclerosis (MS) lesions stay inflamed for very long periods of time. This type of inflammation is not affected by any MS medications. These lesions can lead to slow worsening of MS symptoms.
- Trial name
- NCT04742400
- Testing
- tolebrutinib 60mg, tolebrutinib 120mg
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)